home / stock / ktta / ktta quote
Last: | $5.075 |
---|---|
Change Percent: | 0.0% |
Open: | $5.18 |
Close: | $5.075 |
High: | $5.18 |
Low: | $5.0631 |
Volume: | 2,612 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.075 | $5.18 | $5.075 | $5.18 | $5.0631 | 2,612 | 07-05-2024 |
$5.18 | $5.14 | $5.18 | $5.19 | $5.14 | 923 | 07-04-2024 |
$5.18 | $5.14 | $5.18 | $5.19 | $5.14 | 923 | 07-03-2024 |
$5.155 | $4.83 | $5.155 | $5.155 | $4.83 | 2,486 | 07-02-2024 |
$5.25 | $5.25 | $5.25 | $5.25 | $5.25 | 836 | 07-01-2024 |
$5.0607 | $5.28 | $5.0607 | $5.28 | $5 | 700 | 06-28-2024 |
$5.26 | $5.24 | $5.26 | $5.26 | $5.23 | 953 | 06-27-2024 |
$5.2654 | $4.93 | $5.2654 | $5.2654 | $4.93 | 1,174 | 06-26-2024 |
$5.3 | $4.98 | $5.3 | $5.3 | $4.88 | 4,829 | 06-25-2024 |
$4.97 | $4.8 | $4.97 | $4.97 | $4.7999 | 2,556 | 06-24-2024 |
$4.74 | $4.8799 | $4.74 | $4.8799 | $4.74 | 1,605 | 06-21-2024 |
$4.9023 | $5.105 | $4.9023 | $5.1403 | $4.8 | 5,731 | 06-20-2024 |
$5.14 | $5.22 | $5.14 | $5.49 | $5.14 | 2,249 | 06-19-2024 |
$5.14 | $5.22 | $5.14 | $5.49 | $5.14 | 2,249 | 06-18-2024 |
$5.11 | $5.31 | $5.11 | $5.38 | $5.1 | 7,570 | 06-17-2024 |
$5.26 | $5.4 | $5.26 | $5.4 | $5.26 | 3,585 | 06-14-2024 |
$5.6993 | $5.6 | $5.6993 | $5.6993 | $5.45 | 9,741 | 06-13-2024 |
$5.7767 | $5.84 | $5.7767 | $5.9499 | $5.4 | 30,691 | 06-12-2024 |
$5.57 | $5.79 | $5.57 | $6.4999 | $5.57 | 45,483 | 06-11-2024 |
$5.6003 | $5.6003 | $5.6003 | $5.6003 | $5.6003 | 868 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Pasithea Therapeutics Corp. Company Name:
KTTA Stock Symbol:
NASDAQ Market:
Pasithea Therapeutics Corp. Website:
MIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis typ...
-- PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors -- -- PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and binimetinib and similar to trametinib -- -- PAS-004 shows superior activity versus selumetinib and...